Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphocholine SCHEMBL19386100 | 0.89 | CHRM5 (0.42) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL8773459 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL1802772 | 0.86 | CHRM5 (0.42) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL9613934 | 0.86 | LMNA (0.52) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL8011 | 0.86 | LMNA (0.52) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL14742786 | 0.86 | LMNA (0.52) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL6156988 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL8584618 | 0.84 | LMNA (0.50) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL18662890 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 | |
| Phosphocholine SCHEMBL5143800 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2ADRA1ALMNAESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260072020-A1 | PRINTABLE MOLECULE-SELECTIVE CORE-SHELL NANOPARTICLES FOR WEARABLE AND IMPLANTABLE SENSING | CALIFORNIA INST OF TECHN (US) | 2026-03-12 | — | — | US | claimed |
| US-20250188521-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. | 2025-06-12 | — | — | US | claimed |
| CN-119529204-A | Triblock expansion viscosity-increasing carbon dioxide channeling profile control agent and preparation method thereof | 中国石油大学(华东) | 2025-02-28 | — | — | CN | claimed |
| US-12220550-B2 | Transdermal delivery device, methods of using and making the same | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-02-11 | — | — | US | claimed |
| US-20240167089-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-23 | — | — | US | claimed |
| US-20240167087-A1 | MULTI-DIMENSIONAL POLYMER SCAFFOLDS FOR NUCLEIC ACID ANALYSES | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-05-23 | — | — | US | claimed |
| EP-4371653-A1 | FABRICATION OF FILTRATION MEMBRANES | Trustees of Tufts College (US) | 2024-05-22 | — | — | EP | claimed |
| CN-114957721-B | Zwitterionic hydrogel and preparation method and application thereof | 四川大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117757127-A | Preparation method of polyethylene material with biocompatibility and application of polyethylene material in medical field | 华东理工大学 | 2024-03-26 | — | — | CN | claimed |
| US-11884977-B2 | Nanoarrays and methods of use thereof | Singular Genomics Systems, Inc. (US) | 2024-01-30 | — | — | US | claimed |
| EP-3074440-A1 | MIKTO-ARM BRANCHED POLYMERS | Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) (AU) | 2016-10-05 | — | — | EP | claimed |
| WO-2016109621-A1 | ZWITTERIONIC COPOLYMERS FOR FOULING RESISTANT FILTRATION MEMBRANES | TUFTS UNIVERSITY (US) | 2016-07-07 | — | — | WO | claimed |
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2015-06-18 | — | — | US | claimed |
| WO-2015077831-A1 | MIKTO-ARM BRANCHED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-06-04 | — | — | WO | claimed |
| WO-2014190398-A1 | INHIBITION OF AMYLOID FIBRIL FORMATION | THE UNIVERSITY OF MELBOURNE (AU) | 2014-12-04 | — | — | WO | claimed |
| US-20130276407-A1 | Packaging Solutions | SANTARUS, INC. | 2013-10-24 | — | — | US | claimed |
| US-20120290075-A1 | MODIFICATION OF BIOABSORBABLE STENT TO REDUCE THROMBOGENECITY | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2012-11-15 | — | — | US | claimed |
| US-20110251677-A1 | Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2011-10-13 | — | — | US | claimed |
| WO-2009055306-A2 | COATING DESIGNS FOR THE TAILORED RELEASE OF DUAL DRUGS FROM POLYMERIC COATINGS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-20090104247-A1 | Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2009-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164853-A1 | PROSTACYCLIN COMPOSITIONS FOR REGULATION OF FRACTURE REPAIR AND BONE FORMATION | PTGIR, PTGIS, PTGS1 | SMN1; SMN2 4839/4885ADRA1A 1217/4885LMNA 2695/4885 |
| US-20260072020-A1 | PRINTABLE MOLECULE-SELECTIVE CORE-SHELL NANOPARTICLES FOR WEARABLE AND IMPLANTABLE SENSING | MIF, HMOX2, HMOX1 | SMN1; SMN2 2725/4885ADRA1A 1924/4885LMNA 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.